KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Net Margin: 2018-2025

Historic Net Margin for Castle Biosciences (CSTL) over the last 8 years, with Sep 2025 value amounting to -0.60%.

  • Castle Biosciences' Net Margin fell 325.00% to -0.60% in Q3 2025 from the same period last year, while for Sep 2025 it was -3.55%, marking a year-over-year decrease of 550.00%. This contributed to the annual value of 5.49% for FY2024, which is 3164.00% up from last year.
  • As of Q3 2025, Castle Biosciences' Net Margin stood at -0.60%, which was down 111.41% from 5.29% recorded in Q2 2025.
  • Over the past 5 years, Castle Biosciences' Net Margin peaked at 11.11% during Q4 2024, and registered a low of -91.70% during Q1 2022.
  • Moreover, its 3-year median value for Net Margin was -3.47% (2024), whereas its average is -11.47%.
  • Its Net Margin has fluctuated over the past 5 years, first crashed by 7,294bps in 2022, then skyrocketed by 6,600bps in 2024.
  • Quarterly analysis of 5 years shows Castle Biosciences' Net Margin stood at -25.68% in 2021, then tumbled by 2,810bps to -53.78% in 2022, then spiked by 4,988bps to -3.90% in 2023, then spiked by 1,501bps to 11.11% in 2024, then slumped by 325bps to -0.60% in 2025.
  • Its Net Margin was -0.60% in Q3 2025, compared to 5.29% in Q2 2025 and -29.38% in Q1 2025.